Clinical trials: PD-1 Inhibitors
HPV-positive Oropharyngeal Squamous Cell Carcinoma
Intranasal WSK-IM05 Vaccine Plus Tislelizumab as Neoadjuvant Therapy for HPV+ OPSCC
This phase I, open-label, single-arm trial uses a "3+3" dose-escalation design to evaluate the safety, tolerability, and preliminary efffcacy of intranasal WSK-IM05 vaccine combined with tislelizumab as neoadjuvant therapy in…
- Trial name
- NCT07565740
- Testing
- WSK-IM05 (4×10^10 vp), WSK-IM05 (8×10^10 vp), WSK-IM05 (1.6x10^11 vp)
- Where
- China
- Volunteers
- 9 people
- Sponsor
- West China Hospital
Hypopharyngeal Neoplasm Malignant Primary
Toripalimab Plus TPF Chemotherapy and Radiotherapy for LA-HPSCC
TPF is the standard regime of inductive chemotherapy for squamous carcinoma of head and neck. If the primary tumor shrinks obviously (complete remission or >75% partial remission )after inductive chemotherapy, CCRT is suggested…
- Trial name
- NCT04624308
- Testing
- Toripalimab
- Where
- China
- Volunteers
- 81 people
- Sponsor
- Sun Yan
Classical Hodgkin Lymphoma, Refractory or Relapsed Classical Hodgkin Lymphoma
PD-1 Inhibitor or PD-1 Inhibitor Plus GVD for Relapsed/Refractory CHL
This phase 2 trial studies the efficacy and safety of PD-1 inhibitor monotherapy or PD-1 inhibitor with GVD (Gemcitabine, Vinorelbine and Doxorubicin Liposome) regimen for relapsed or refractory classical Hodgkin lymphoma (CHL)…
- Trial name
- NCT04624984
- Testing
- PD-1 inhibitor, PD-1 inhibitor, gemcitabine, vinorelbine and doxorubicin liposome
- Where
- 3 sites in China
- Volunteers
- 42 people
- Sponsor
- Sun Yat-sen University
Rectal Cancer, Neoadjuvant Therapies
Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II)
Most rectal cancers are microsatellite stable (MSS) or mismatch repair-proficient (pMMR) and respond poorly to PD-1 inhibitors. Radiotherapy can enhance tumor antigen release and improve responsiveness to PD-1 blockade in…
- Conditions
- Rectal Cancer, Neoadjuvant Therapies, Immune Checkpoint Therapy, Radiotherapy
- Trial name
- NCT06958432
- Testing
- Node-Sparing Radiotherapy plus Chemotherapy and PD-1 inhibitor, Conventional Radiotherapy plus Chemotherapy
- Where
- China
- Volunteers
- 430 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
HCC - Hepatocellular Carcinoma, Hepatic Arterial Infusion Chemotherapy
HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416)
The purpose of this study is to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) in combination with PD-1 inhibitors and Lenvatinib in patients with high tumor burden advanced-stage hepatocellular…
- Conditions
- HCC - Hepatocellular Carcinoma, Hepatic Arterial Infusion Chemotherapy, BCLC Stage C Hepatocellular Carcinoma, Lenvatinib
- Trial name
- NCT06631326
- Testing
- hepatic artery infusion chemotherapy, Lenvatinib + PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 244 people
- Sponsor
- First Hospital of China Medical University
Metastatic Malignant Solid Neoplasm, Radiotherapy
Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Solid Tumors
Preclinical and clinical studies have shown that intestinal low dose radiotherapy (ILDR) can enhance antitumor immunity and response to immune checkpoint blockade (ICB).
- Conditions
- Metastatic Malignant Solid Neoplasm, Radiotherapy, Immune Checkpoint Blockade, Resistance to Immunotherapy
- Trial name
- ILDR-01 (NCT06076135)
- Testing
- Intestinal Low Dose Radiotherapy-1Gy, PD-1/PD-L1 Inhibitors
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Chuangzhen Chen
Unspecified Adult Solid Tumor, Protocol Specific
Measuring Biomarker Response to AMP-514 in Blood Samples From Patients With Solid Tumors Undergoing Radiotherapy
This pilot research trial studies the response in blood cells to AMP-514, a drug shown to increase immune response (capacity to fight against infections and cancer) against cancer in patients with solid tumors undergoing…
- Trial name
- NCT02153151
- Testing
- Cytology specimen, Laboratory biomarker analysis
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
HCC, Adjuvant Therapy
Intra-Tumoral Vascular Growth Patterns is a Robust Indicator of Adjuvant Therapy Following Liver Resection in HCC
Vessels that encapsulate tumor clusters (VETC) is an invasive metastatic factor in HCC independent of the epithelial mesenchyme transition (EMT), and VETC positive patients have a higher rate of postoperative recurrence.
- Conditions
- HCC, Adjuvant Therapy, Immunotherapy, Recurrence
- Trial name
- NCT06461936
- Testing
- Sintilimab, Lenvatinib
- Where
- China
- Volunteers
- 620 people
- Sponsor
- Chen Xiaoping
Pancreatic Cancer, Pancreas Adenocarcinoma
A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer
Chemotherapy regimens for pancreatic cancer can now stabilize a patient's cancer and/or place some patients in remission or partial remission.
- Conditions
- Pancreatic Cancer, Pancreas Adenocarcinoma, Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer
- Trial name
- NCT03331562
- Testing
- Pembrolizumab, paricalcitol
- Where
- 6 sites in United States
- Volunteers
- 24 people
- Sponsor
- Translational Genomics Research Institute
Recurrent Head and Neck Squamous Cell Carcinoma
Anti-PD-1 Therapy in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma
The goal of this clinical trial is to determine whether a perioperative PD-1 antibody-based treatment strategy, consisting of neoadjuvant PD-1 antibody plus chemotherapy followed by adjuvant PD-1 antibody after surgery, improves…
- Trial name
- neo-Recur (NCT07751289)
- Testing
- Neoadjuvant PD-1 antibody plus chemotherapy, surgery, Adjuvant PD-1 antibody
- Volunteers
- 217 people
- Sponsor
- Yanjie Zhang, MD
Lung Cancer, Rechallenge
PD-L1 Inhibitor Rechallenge After Immunotherapy-Related Pneumonitis in Patients With Lung Cancer
This multicenter observational study will evaluate the safety and effectiveness of immune checkpoint inhibitor rechallenge in adults with lung cancer who developed checkpoint inhibitor pneumonitis.
- Conditions
- Lung Cancer, Rechallenge, Checkpoint Inhibitor Pneumonitis
- Trial name
- NCT07775820
- Testing
- PD-L1 Inhibitor Rechallenge, PD-1 Inhibitor Rechallenge, No Immune Checkpoint Inhibitor Rechallenge
- Where
- 5 sites in China
- Volunteers
- 150 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Recurrent or Metastatic Head and Neck Carcinoma
Sacituzumab Tirumotecan Plus Immunotherapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
This is a single-center, open-label phase 2 study evaluating sacituzumab tirumotecan in combination with an immune checkpoint inhibitor in patients with previously treated recurrent or metastatic head and neck squamous cell…
- Trial name
- NCT07686588
- Testing
- Sacituzumab Tirumotecan Plus Immune Checkpoint Inhibitor
- Volunteers
- 20 people
- Sponsor
- Biying Chen
Radiotherapy, PD-1 Inhibitor
Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma
This is a single-arm, multicenter, prospective, open-label phase II clinical trial of multi-target radiotherapy combined with PD-1 monoclonal antibody and capecitabine maintenance therapy treating oligometastatic nasopharyngeal…
- Conditions
- Radiotherapy, PD-1 Inhibitor, Capecitabine, Nasopharyngeal Carcinoma
- Trial name
- NCT05290194
- Testing
- SBRT radiotherapy + Conventionally fractionated radiotherapy, PD-1 inhibitor, Capecitabine
- Where
- China
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
Hepatocellular Carcinoma
Ablation Combined With PD-1 in HCC: Phase II Study
This is a Phase 2, single arm, single center study designed to evaluate the safety and tolerability of radiofrequency or microwave ablation combined with PD-1 monoclonal antibody in patients with hepatocellular carcinoma(HCC)…
- Trial name
- NCT04652440
- Testing
- PD-1 monoclonal antibody, Radiofequencey or microwave ablation
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
High-grade Glioma
A Study on the Novel Oncolytic Virus Combined With PD-1 Inhibitor in the Treatment of Recurrent High-grade Glioma
A single-arm clinical study on the efficacy and safety of the novel oncolytic virus Ad-TD-nsIL12 combined with PD-1 inhibitors in the treatment of recurrent high-grade glioma
- Trial name
- NCT07472790
- Testing
- Novel oncolytic virus Ad-TD-nsIL12（BioTTT001）
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Nasopharyngeal Carcinoma
Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC
This is a randomized clinical trial comparing neoadjuvant and adjuvant PD-1 inhibitor Toripalimab plus neoadjuvant chemotherapy and concurrent chemoradiotherapy versus neoadjuvant chemotherapy and concurrent chemoradiotherapy…
- Trial name
- NCT04557020
- Testing
- PD-1 antibody, Gemcitabine, Cisplatin
- Where
- 7 sites in China
- Volunteers
- 200 people
- Sponsor
- Jiangxi Provincial Cancer Hospital
HER2-positive or Mutated Advanced Colorectal Cancer
Study of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy
This study will explore the efficacy and safety of tislelizumab (PD1 inhibitor) combined with DisitamabVedotin (ADC) and pyrotinib maleate (TKI) in the treatment of HER2-positive or mutated advanced colorectal cancer who have…
- Trial name
- NCT05350917
- Testing
- Tislelizumab
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Esophageal Squamous Cell Carcinoma (ESCC)
PD-1 Inhibitors Combined With Local Therapy at Different Timings in Oligometastatic ESCC
Although immunotherapy combined with chemotherapy has become the first-line standard regimen for advanced esophageal squamous cell carcinoma (ESCC) and improved clinical outcomes in advanced patients, the prognosis of patients…
- Trial name
- ESO-shanghai31 (NCT07697859)
- Testing
- Two arms adopt local intervention administered at distinct timings.
- Where
- China
- Volunteers
- 354 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma, Lenvatinib
HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma
Hepatic arterial infusion chemotherapy (HAIC) plus lenvatinib and programmed cell death protein-1 (PD-1) inhibitor have shown promising results for advanced hepatocellular carcinoma (HCC).
- Conditions
- Hepatocellular Carcinoma, Lenvatinib, PD-1 Inhibitor, Hepatic Arterial Infusion Chemotherapy
- Trial name
- NCT06333561
- Testing
- Hepatic arterial infusion chemotherapy, Lenvatinib, Tislelizumab
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Sun Yat-sen University
Personalized Neoantigen Vaccine in Combination With Anti-PD-1 Inhibitors in Standard Therapy-Failed and Adjuvant Therapy, Gastrointestinal Tumors
Personalized mRNA Cancer Vaccine for Gastrointestinal Solid Tumor Treatment
Evaluating the efficacy and safety of Neoantigen Personalized Cancer Vaccine deepGeneAI-001 in combination with Sintilimab in the treatment of Gastrointestinal Solid Tumors
- Trial name
- PCV-GSTT (NCT07067385)
- Testing
- Neoantigen Personalized Cancer Vaccine
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Ruijin Hospital